SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.20 |
| Enterprise Value ($M) | -0.75 |
| Book Value ($M) | 3.35 |
| Book Value / Share | 0.07 |
| Price / Book | 1.85 |
| NCAV ($M) | 3.33 |
| NCAV / Share | 0.07 |
| Price / NCAV | 1.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -5.04 |
| Return on Assets (ROA) | -7.33 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.82 |
| Current Ratio | 1.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 7.39 |
| Assets | 7.41 |
| Liabilities | 4.06 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 3.20 | 57.10 | |
| 13D | Cortice Biosciences, Inc. | 5.70 | ||
| 13G | Forster Robert | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,812,041 | 19,255,479 | 35.38 | |
| 2,731,064 | 7,263,151 | 37.60 | |
| 5,892,611 | 13,086,359 | 45.03 | |
| 3,272,198 | 7,712,872 | 42.43 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CLNN – Clene Inc. | CLRB – Cellectar Biosciences, Inc. |
| CMPX – Compass Therapeutics, Inc. | CNTX – Context Therapeutics Inc. |
| COCP – Cocrystal Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io